Your browser is no longer supported. Please, upgrade your browser.
ABBV AbbVie Inc. daily Stock Chart
AbbVie Inc.
IndexS&P 500 P/E17.01 EPS (ttm)3.65 Insider Own0.10% Shs Outstand1.62B Perf Week0.99%
Market Cap100.34B Forward P/E9.65 EPS next Y6.44 Insider Trans-3.56% Shs Float1.59B Perf Month1.16%
Income5.95B PEG1.18 EPS next Q1.26 Inst Own69.40% Short Float1.95% Perf Quarter6.43%
Sales25.64B P/S3.91 EPS this Y16.20% Inst Trans-1.92% Short Ratio4.30 Perf Half Y-2.71%
Book/sh2.87 P/B21.63 EPS next Y17.21% ROA9.40% Target Price69.78 Perf Year14.70%
Cash/sh3.97 P/C15.62 EPS next 5Y14.38% ROE111.30% 52W Range52.02 - 66.82 Perf YTD0.15%
Dividend2.56 P/FCF35.27 EPS past 5Y10.90% ROI18.00% 52W High-7.08% Beta1.56
Dividend %4.12% Quick Ratio1.50 Sales past 5Y8.00% Gross Margin77.30% 52W Low19.36% ATR0.86
Employees30000 Current Ratio1.70 Sales Q/Q6.20% Oper. Margin36.60% RSI (14)59.17 Volatility1.21% 1.44%
OptionableYes Debt/Eq7.95 EPS Q/Q-7.30% Profit Margin23.20% Rel Volume0.90 Prev Close61.94
ShortableYes LT Debt/Eq7.86 EarningsJan 27 BMO Payout62.10% Avg Volume7.20M Price62.09
Recom2.50 SMA201.82% SMA501.06% SMA2001.11% Volume6,507,100 Change0.24%
Oct-31-16Downgrade Credit Suisse Outperform → Neutral
Oct-18-16Initiated Leerink Partners Mkt Perform $70
Sep-08-16Downgrade JP Morgan Overweight → Neutral
Sep-02-16Initiated Raymond James Outperform $82
Jun-08-16Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-06-16Initiated Societe Generale Sell $47
Mar-15-16Initiated Deutsche Bank Hold $63
Feb-23-16Upgrade Citigroup Neutral → Buy
Dec-01-15Downgrade Barclays Overweight → Equal Weight $73 → $72
Nov-02-15Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-23-15Reiterated UBS Buy $81 → $78
Sep-28-15Upgrade Citigroup Sell → Neutral
Jul-22-15Initiated Sun Trust Rbsn Humphrey Buy
Jun-17-15Initiated Piper Jaffray Overweight
Jun-08-15Reiterated Jefferies Buy $86 → $90
May-28-15Resumed Morgan Stanley Equal-Weight $72
May-27-15Resumed JP Morgan Overweight $75
Jan-06-15Reiterated UBS Buy $72 → $76
Nov-26-14Reiterated Argus Buy $65 → $85
Nov-14-14Initiated Deutsche Bank Buy $80
Feb-27-17 04:00AM  AbbVie Receives CHMP Positive Opinion for Eight-Week Treatment Option with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) for Patients with Genotype 1b Chronic Hepatitis C PR Newswire
01:51AM  Facing Criticism, Drug Makers Keep Lid On Price Increases at The Wall Street Journal
Feb-26-17 08:03PM  Drug Companies Keep Lid on Price Increases at The Wall Street Journal
Feb-24-17 04:14PM  Gilead, AbbVie Could Perk Up On Merck's Hep C Downfall: Leerink
10:57AM  3 Incredibly Cheap Biotech Stocks at Motley Fool
Feb-23-17 05:08PM  2 Dividend Aristocrats Trading At A Discount
05:06PM  AbbVie Stronger Bet Than Gilead, Amgen At Least Until 2020: Leerink
01:04PM  ABBVIE INC. Financials
12:55PM  Questions Linger About AbbVie's AndroGel at Investopedia
10:48AM  These 3 Dividend Stocks Are Ridiculously Cheap at Motley Fool
Feb-21-17 03:11PM  AbbVie Declares Quarterly Dividend
11:11AM  AbbVie Inc (ABBV) In Share Buyback Plan For The Third Year In A Row at Insider Monkey
07:15AM  AbbVie, Inc. breached its 50 day moving average in a Bullish Manner : ABBV-US : February 21, 2017
Feb-17-17 12:22PM  ABBVIE INC. Files SEC form 10-K, Annual Report
09:07AM  Parsabiv Is Expected to Boost Amgens Revenues in 2017
08:13AM  Pfizer's Xeljanz Combo Comparable to AbbVie's Humira
08:00AM  AbbVie Announces $5 Billion Increase to Stock Repurchase Program PR Newswire
Feb-16-17 01:35PM  NICE Rejects AbbVies Leukemia Drug Venclexta at Investopedia
01:15PM  UK National Institute For Health And Care Excellence Rejects Leukemia Drug From AbbVie Inc (ABBV) at Insider Monkey
12:41PM  AbbVie Declares Quarterly Dividend PR Newswire
09:42AM  Why I Just Bought AbbVie Stock at Motley Fool
08:16AM  Pfizer says rheumatoid arthritis drug is comparable to Humira as combination treatment but not alone at MarketWatch
Feb-15-17 10:42AM  Eli Lilly Is Great Stock to Buy Now
08:10AM  No Joke: Johnson & Johnson Could Grow Sales by 5% (or More) Annually Over the Next Decade at Motley Fool
08:01AM  AbbVie to Present at the Cowen and Company 37th Annual Health Care Conference PR Newswire
Feb-14-17 10:28AM  3 Top Biotech Stocks to Buy on Sale at Motley Fool
02:00AM  These drug and medical device companies made the most payments to N.Y.C. hospitals at
Feb-11-17 09:05AM  Better Buy: AbbVie Inc. vs. Eli Lilly at Motley Fool
Feb-10-17 04:20PM  Here's Why M&A Has Tesaro's Stock Soaring 40% In 2017 at Motley Fool
03:42PM  3 Trump-Proof Dividend Stocks to Buy Right Now at Motley Fool
08:35AM  Are Short Sellers Doubting Trump by Hiking Bets in Major Pharma?
Feb-09-17 01:35PM  Why OraSure Technologies, Inc. Leaped Higher Today at Motley Fool
08:50AM  10 Best Dividend-Paying Stocks for 2017 at Kiplinger
Feb-08-17 03:33PM  Finding the Best Value Investment in Healthcare at Investopedia
11:39AM  Gilead Hepatitis C Meltdown Raises Troubling Question: Is Curing Disease Bad for Business?
09:30AM  The Zacks Analyst Blog Highlights: Apple, Visa and AbbVie
Feb-07-17 06:58PM  Gilead 2017 hepatitis C sales forecast disappoints, shares drop
05:22PM  Streamlined FDA Approval Process Would Boost Drug Makers
01:24PM  Earnings No Longer a Headwind for Stocks
Feb-06-17 04:23PM  AbbVie, Merck Pressure Gilead's 2017 Hep C Unit; GSK Battles HIV Biz
09:34AM  Marijuana's Patent Spree Puts The 'High' In High Tech at Forbes
Feb-03-17 10:23AM  Merck's Sneak Peek Into Its Drug Pricing May Not Be Enough to Satisfy Skeptics at Motley Fool
08:25AM  Jefferies Adds Big Dividend-Paying Leader to Franchise Picks List
Feb-02-17 04:53PM  [$$] Amgen's Profit Rises on Improved Margins, Steady Top-line Growth at The Wall Street Journal
03:18PM  AbbVie's Hepatitis C Treatment Under FDA Review
01:10PM  Sanofi Genzyme head weighs in on drug price debate at
12:11PM  ETFs with exposure to AbbVie, Inc. : February 2, 2017
10:54AM  Roche (RHHBY) Beats on Earnings in 2016, Misses on Sales
08:41AM  3 Stocks to Buy With Dividends Yielding More Than 3% at Motley Fool
08:00AM  U.S. FDA Grants Priority Review to AbbVie for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) PR Newswire
07:36AM  AbbVie Is Well-Positioned to Meet Long-Term Financial Targets by 2020
07:00AM  3 Pharmaceutical Stocks With Bigger Dividends Than Johnson & Johnson at Motley Fool
06:51AM  AbbVie (ABBV) HCV Regimen Gets Priority Review in Canada
06:27AM  Biotech Stock Roundup: Celgene, Biogen, ABBV Post Q4 Results, Catabasis Falls on DMD Data
Feb-01-17 10:36AM  Incremental R&D Expenses May Pressure AbbVies 2017 Operating Margins
09:08AM  AbbVie Projects Robust Revenue Growth for 2017
08:00AM  Health Canada Grants Priority Review to AbbVie's Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) PR Newswire
08:00AM  Health Canada Grants Priority Review to AbbVie's Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) CNW Group
07:38AM  Imbruvica Expected to Drive AbbVies Revenue Growth
12:51AM  [$$] Trumps Criticism of Imports Adds to Drugmakers Headaches at The Wall Street Journal
Jan-31-17 08:49PM  [$$] Trumps Criticism of Imports Adds to Drugmakers Headaches at The Wall Street Journal
06:47PM  [$$] Trump's Criticism of Imports Adds to Drugmakers' Headaches at The Wall Street Journal
05:36PM  Humira Witnessed Solid Revenue Growth in 4Q16
03:39PM  AbbVie Reported Lower-than-Expected Revenue Growth in 4Q16
Jan-30-17 04:28PM  Better Buy: AbbVie Inc. vs. Pfizer at Motley Fool
03:24PM  Amgen Gets European Nod for Humira Biosimilar at Investopedia
10:36AM  Gilead Sciences Plans to Focus on Its HCV Franchise in 2017
10:30AM  New competition took a bite out of J&Js drug sales, but dont expect the trend to dominate this earnings season at MarketWatch
09:38AM  AbbVie, Inc. :ABBV-US: Earnings Analysis: 2016 By the Numbers : January 30, 2017
08:21AM  Key Takeaways from AbbVie's Q4 Call: Humira and the Pipeline
07:43AM  Here's the Best Dividend Stock in Big Pharma at Motley Fool
07:37AM  Pfizer (PFE) Gets Positive CHMP Opinion for Arthritis Drug
07:34AM  Amgen Wins Favorable CHMP Opinion for Humira Biosimilar
07:00AM  AbbVie Looks Undervalued at Morningstar
Jan-29-17 01:33PM  AbbVie to Start Study on Alzheimer's Treatment
Jan-28-17 12:43PM  You Can Also Get High on Marijuana Stocks -- Here's How
12:28PM  Better Buy: Johnson & Johnson vs. AbbVie at Motley Fool
Jan-27-17 04:17PM  AbbVie Plummets To 2017 Low On Light Q4 Sales, Though EPS Meets
02:42PM  AbbVie (ABBV) Q4 Earnings Meet Estimates, Revenues Lag
01:06PM  AbbVie's revenue miss clouds strong Humira U.S. sales
11:59AM  Edited Transcript of ABBV earnings conference call or presentation 27-Jan-17 2:00pm GMT
11:52AM  AbbVie Reports 4th-Quarter 2016 Results
09:34AM  [$$] AbbVie Revenue Rises But Profit Falls at The Wall Street Journal
09:27AM  AbbVie (ABBV) Reports In-Line Q4 Earnings, Revenues Miss
09:00AM  AbbVie Inc Earnings Call scheduled for 9:00 am ET today
08:45AM  AbbVie Slides on Mixed Q4 Earnings
08:24AM  Drugmaker AbbVie's quarterly revenue misses estimates
08:06AM  AbbVie Inc. reports fourth-quarter revenue miss and earnings match at MarketWatch
08:00AM  AbbVie revenue rises 6.2 pct
07:58AM  AbbVie meets 4Q profit forecasts
07:54AM  ABBVIE INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
07:48AM  AbbVie Reports Full-Year and Fourth-Quarter 2016 Financial Results PR Newswire
07:26AM  Market Recon: Danger Is Coming to a Market Near You
07:07AM  Q4 2016 AbbVie Inc Earnings Release - Before Market Open
Jan-26-17 05:15PM  [$$] Celgene To Acquire Biotech Startup Delinia For Up to $775 Million at The Wall Street Journal
03:10PM  Here are 10 biggest venture-backed M&A deals of all time at
10:42AM  Johnson & Johnson's Most Exciting Opportunity at Motley Fool
09:50AM  Short Sellers Run for Cover From Major Pharma
09:32AM  Biogen (BIIB) Q4 Earnings Top Estimates; '17 Sales View Soft
09:00AM  3 Dividend Aristocrats to Buy for Income and Growth at Kiplinger
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for adults with genotype 1 chronic hepatitis. It also provides Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent respiratory syncytial virus infection in high risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, and endometriosis and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; TriCor, Trilipix, and Niaspan to treat metabolic conditions characterized by high cholesterol and/or high triglycerides; and Zemplar to treat secondary hyperparathyroidism. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has strategic collaboration with C2N Diagnostics; Calico Life Sciences LLC; Infinity Pharmaceuticals, Inc.; Ablynx NV; Galapagos NV; Alvine Pharmaceuticals, Inc.; and Zebra Biologics Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SALEKI-GERHARDT AZITASVP, OperationsFeb 02Option Exercise27.292,40065,4965,431Feb 03 05:21 PM
CHASE WILLIAM JEVP, Chief Financial OfficerDec 02Option Exercise27.296,600180,114178,970Dec 02 05:08 PM
CHASE WILLIAM JEVP, Chief Financial OfficerDec 02Sale59.196,600390,654172,370Dec 02 05:08 PM
HURWICH THOMAS A.VP, ControllerNov 16Option Exercise28.863,10089,47564,549Nov 18 05:39 PM
HURWICH THOMAS A.VP, ControllerNov 16Sale62.003,100192,20061,449Nov 18 05:39 PM
Schumacher Laura JExecutive Vice PresidentSep 07Sale65.0050,0003,250,000144,138Sep 09 05:38 PM
Schumacher Laura JExecutive Vice PresidentJun 24Option Exercise27.62186,1065,140,971380,244Jun 28 05:47 PM
Schumacher Laura JExecutive Vice PresidentJun 24Sale60.03186,10611,171,173194,138Jun 28 05:47 PM
GONZALEZ RICHARD AChairman of the Board and CEOJun 02Sale63.82285,95318,249,712338,421Jun 03 05:26 PM
GONZALEZ RICHARD AChairman of the Board and CEOMay 11Sale63.8039,0002,488,200338,421May 13 05:11 PM
HURWICH THOMAS A.VP, ControllerMay 10Option Exercise27.296,000163,74068,204May 12 05:44 PM
HURWICH THOMAS A.VP, ControllerMay 10Sale63.596,000381,54162,204May 12 05:44 PM
ALBAN CARLOSEVP, Commercial OperationsMay 10Sale63.5247,4383,013,262149,444May 12 05:39 PM
Schumacher Laura JExecutive Vice PresidentMar 08Sale56.0925,0001,402,341194,138Mar 08 05:23 PM